- Home
- VRPX vs QLGN Comparison
VRPX vs QLGN Comparison
Compare VRPX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRPX
- QLGN
- Stock Information
- Founded
- VRPX 2016
- QLGN 1996
- Country
- VRPX United States
- QLGN United States
- Employees
- VRPX N/A
- QLGN 4
- Industry
- VRPX Medicinal Chemicals and Botanical Products
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- VRPX Health Care
- QLGN Health Care
- Exchange
- VRPX Nasdaq
- QLGN Nasdaq
- Market Cap
- VRPX 3.7M
- QLGN 2.7M
- IPO Year
- VRPX 2021
- QLGN N/A
- Fundamental
- Price
- VRPX $0.62
- QLGN $3.60
- Analyst Decision
- VRPX Hold
- QLGN
- Analyst Count
- VRPX 1
- QLGN 0
- Target Price
- VRPX N/A
- QLGN N/A
- AVG Volume (30 Days)
- VRPX 108.5K
- QLGN 226.0K
- Earning Date
- VRPX 11-26-2024
- QLGN 11-29-2024
- Dividend Yield
- VRPX N/A
- QLGN N/A
- EPS Growth
- VRPX N/A
- QLGN N/A
- EPS
- VRPX N/A
- QLGN N/A
- Revenue
- VRPX N/A
- QLGN N/A
- Revenue This Year
- VRPX N/A
- QLGN N/A
- Revenue Next Year
- VRPX N/A
- QLGN N/A
- P/E Ratio
- VRPX N/A
- QLGN N/A
- Revenue Growth
- VRPX N/A
- QLGN N/A
- 52 Week Low
- VRPX $0.36
- QLGN $3.55
- 52 Week High
- VRPX $7.60
- QLGN $39.15
- Technical
- Relative Strength Index (RSI)
- VRPX 43.76
- QLGN 25.42
- Support Level
- VRPX $0.55
- QLGN $3.71
- Resistance Level
- VRPX $0.79
- QLGN $4.56
- Average True Range (ATR)
- VRPX 0.07
- QLGN 0.65
- MACD
- VRPX -0.01
- QLGN -0.06
- Stochastic Oscillator
- VRPX 27.96
- QLGN 2.08
About VRPX Virpax Pharmaceuticals Inc.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.